Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVaddadi G.en
dc.contributor.authorVaddadi K.S.en
dc.contributor.authorSoosai E.en
dc.date.accessioned2021-05-14T11:04:55Zen
dc.date.available2021-05-14T11:04:55Zen
dc.date.copyright2003en
dc.date.created20030421en
dc.date.issued2012-10-17en
dc.identifier.citationBritish Journal of Clinical Pharmacology. 55 (3) (pp 307-309), 2003. Date of Publication: 01 Mar 2003.en
dc.identifier.issn0306-5251en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/32693en
dc.description.abstractAims: To compare plasma and red-cell selenium concentrations of schizophrenic patients treated with clozapine, with healthy controls and patients with mood disorders. Method(s): Plasma and red-cell selenium concentrations were measured in random venous blood samples from four groups: mood disorder (n = 36), schizophrenics treated with clozapine (n = 54), schizophrenics not treated with clozapine (n = 41) and a healthy control group (n = 56). Assays were performed by an independent laboratory that was blinded to the patient groups and specializes in estimating trace metal concentrations. Result(s): Selenium concentrations in plasma and red cells were found to be significantly lower in schizophrenic patients treated with clozapine as compared with all other groups. Conclusion(s): Selenium is an essential antioxidant. Its deficiency has been implicated in myocarditis and cardiomyopathy. Low selenium concentrations in clozapine-treated patients may be important in the pathogenesis of life threatening cardiac side-effects associated with clozapine. Further clinical studies are being conducted to explore this important clinical observation and its therapeutic implications.en
dc.languageenen
dc.languageEnglishen
dc.publisherBlackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)en
dc.titleLow blood selenium concentrations in schizophrenic patients on clozapine.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1365-2125.2003.01773.xen
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid12630982 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12630982]en
dc.identifier.source36390761en
dc.identifier.institution(Vaddadi) Department of Psychological Medicine, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia (Soosai) Clayton Comm. Mental Health Service, 270 Clayton Road, Clayton, Vic. 3168, Australia (Vaddadi) Austin/Repatriation Medical Centre, Studley Road, Heidelberg, Vic. 3084, Australiaen
dc.description.addressK.S. Vaddadi, Department of Psychological Medicine, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia. E-mail: vaddadik@hotmail.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCardiomyopathy Clozapine Myocarditis Schizophrenia Seleniumen
dc.identifier.authoremailVaddadi K.S.; vaddadik@hotmail.comen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Collections:Articles
Show simple item record

Page view(s)

36
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.